Neuromodulation Technologies - A Strategic Perspective (TechVision)

Neuromodulation Technologies - A Strategic Perspective (TechVision)

RELEASE DATE
24-Feb-2016
REGION
Global
Research Code: D6D1-01-00-00-00
SKU: HC02621-SA-TR_16743

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC02621-SA-TR_16743

$4,950.00

$3,712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Over the past decade, global industry leaders offering neuromodulation technologies have been largely successful in implementing large scale value stream transformation programs in setting a mature cost-to-serve model. However, understanding the gaps between OEM initiatives in delivering value to care payers and payer demands have been limited. This research service offers a strategic perspective on the industry, analyzing the gaps between technology push-pull factors that are poised to enable OEMs sustain both volume growth and margin. This research also examines how OEMs can shift from a value-to-cost model to a value-to-serve business model, which plays a lead role in delivering personalized value to healthcare payers and care providers.

Table of Contents

1.1 Scope of Research

1.2 Research Methodology

2.1 Transferring Cost Efficiencies across the Value Chain

2.2 IP Filings Focus on Minimally Invasive Therapies

2.3 Clinical Trials to Diversify Product Pipeline

2.4 Differentiate Products by Building a Value-driven Organization

3.1 Invasive, Minimally Invasive and Non-Invasive Neuromodulation Technologies

3.2 High Market Demand for Non-Invasive Methods and Therapies for Lifestyle Disorders

3.3 Spinal Cord and Deep Brain Stimulation Systems, Global, 2016

3.4 Vagus Nerve and Other Stimulation Systems, Global, 2016

3.5 NPD Efforts Focus on Miniaturization of Implants

3.6 Objectives of OEMs Are Aligned to Delivering Personalized Value to Payers

3.7 Focus on Creating Effective Collaboration among Payers Drive Channel Growth

3.8 Neuromodulation Systems, Prices, Global, 2016

3.9 Assessment of Components of Neuromodulation Systems

3.10 Analytical Hierarchy Process: Prioritization of Neuromodulation Technologies

3.11 Performance of Pulse Generator and Lead Precision Is of High Priority

3.12 Functionality of Device Controller and Programmer Are of Least Priority

3.13 Improving the Longevity of Power Supplies and Lead Flexibility

3.14 Payer Preference to Minimally Invasive Therapies for Chronic Conditions

4.1 80% of Market Share Is Owned by Four Companies

4.2 Cost-efficient Value Chain and Consolidation Efforts Drive Profitable Growth

4.3 Better Patient-Physician Collaboration Drive Technology Growth

4.4 Consolidation Trends Pull Prospective Investments within the Global Industry

4.5 OEMs Race against VC/PE Firms to Invest in Neuromodulation Technologies

4.6 Increase in Cross-selling Agreements with Pharmaceutical Companies

4.7 OEMs Place a Premium during Commercialization of Co-created Products

4.8 Established Mid-size Firms Are Partnership Targets in Emerging Markets

4.9 Backward Integration Efforts of OEMs Will Deliver Personalized Value

4.10 VC and Major Pharmaceutical Firms Influence Growth in Delivery of Quality Care

5.1 Centricity between Cost Efficiency and Market Maturity Enabled Customer Value

5.2 Neuromodulation: Key Growth Strategies for a Value-Driven Business Model, Global, 2016

5.3 Value-for-Cost Business Model: OEMs Focus on Cost Savings within the Value-Chain

6.1 A Robust Operations Analytics Framework to Drive Quality Patient Care

6.2 Strategic Partnerships Deliver Sustainable Growth and Value Proposition

7.1 Boston Scientific Leads in IP Creation Activities Worldwide

7.2 Key Patents: Cantilever Electrodes for Transdermal and Transcranial Stimulation

7.3 Key Patents: Optogenetic Therapies for Movement Disorders

7.4 Key Patents: Minimally Invasive Implantable Neurostimulation Systems

7.5 List of Key Industry Participants

Legal Disclaimer

8.1 Analytical Hierarchical Process

8.2 Explanation of Benchmarking Criteria

8.3 Liberatore’s Rating Scale

9.1 The Frost & Sullivan Story

9.2 Value Proposition: Future of Your Company & Career

9.3 Global Perspective

9.4 Industry Convergence

9.5 360º Research Perspective

9.6 Implementation Excellence

9.7 Our Blue Ocean Strategy

Related Research
Over the past decade, global industry leaders offering neuromodulation technologies have been largely successful in implementing large scale value stream transformation programs in setting a mature cost-to-serve model. However, understanding the gaps between OEM initiatives in delivering value to care payers and payer demands have been limited. This research service offers a strategic perspective on the industry, analyzing the gaps between technology push-pull factors that are poised to enable OEMs sustain both volume growth and margin. This research also examines how OEMs can shift from a value-to-cost model to a value-to-serve business model, which plays a lead role in delivering personalized value to healthcare payers and care providers.
More Information
No Index No
Podcast No
WIP Number D6D1-01-00-00-00
Is Prebook No